|
Marketing Authorisations
|
|
|
Inadequate evaluation, frequent and serious adverse effects
|
|
|
|
|
|
Appears to prolong survival in mast cell leukaemia
|
|
|
|
|
|
Improved survival, but adverse effects underestimated
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
First-choice treatments
|
|
|
|
|
|
No reduction in mortality with tranexamic acid
|
|
|
|
|
|